drugset

drugset / Trial / NCT06762132

A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia

NCT06762132 ↗

Phase 0 Recruiting 27 enrolled Zhejiang University Yake Biotechnology Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

A Clinical Study on the Safety and Effectiveness of targeting CD33 CAR-T Cell in the treatment of Relapsed/Refractory Acute Myeloid Leukemia

Timeline

Start: 2025-01-10
Primary completion: 2027-10-30
Completion: 2027-10-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CD33 CAR T-cells	Cell therapy	—	Intravenous

Indications